產品名稱：Haemophilus Influenzae B IgG ELISA
產    地：Demeditec 
產品貨號：DE7704010
產品規格：96 Tests
產品說明：
Special remarks:
1. Introduction
Haemophilus influenzae type B (HiB) is a very common cause of invasive critical infectious diseases in children
up to the age of six. Following infection the symptoms of the disease include: Pericarditis, steomyelitis, meningitis, encephalitis, pneumonia, sinusitis and otitis. In many cases the disease is lethal or leads to neurological damage, which cannot always be prevented by rapid antibiotic therapy.
The underlying reason for the disease is very often a latent immunodeficiency with a specifically reduced humoral immune response to the polyribosylribitolphosphate (PRP) in the polysaccharide encapsulation of the bacterium. In children another reason is the immaturity of the immune system. Today often the term "immunocompromised patients" is used, comprising all acquired and innate specific and unspecific immunodeficiencies.
As a result, in children of 3 months of age or older a vaccination with different sorts of PRP-containing vaccines is recommended. This can lead to a clear reduction in the number of infections with Haemophilus influenzae type B.
The titer of antibodies produced by vaccination can be used to confirm whether the vaccination has been successful. DEMEDITEC HiB IgG is used to measure the level of PRP-specific IgG-antibodies following a 4-6 week period after complete immunization to monitor the humoral immune status of children or other individuals at risk.
2. Indications
Monitoring of the humoral immunostatus after vaccination. Verification of the diagnosis Haemophilus influenzae type B infection by repeated monitoring of antibody concentrations. Risk assessment in immunocompromised patients leading to a failure of vaccination with a PRP-containing vaccine.
This group comprises:
Children under 2 years having had an infection with Haemophilus influenzae type B, children with chronic, recurring bacterial infections of the respiratory tract, children with chronic otitis, patients with confirmed humoral immuno-deficiencies (IgG-2-deficiency, IgA-deficiency), patients with confirmed granulocyte deficiencies, patients under chemo or cytostatic therapy, children after splenectomy, patients with sickle-cell anaemia, patients with trisomy 21 (Down) syndrome, and certain ethnic groups.
3. Test Principle
DEMEDITEC HiB-IgG is a two-step-ELISA. The wells in the ELISA test strips are coated with PRP. During incubation of diluted serum or plasma samples specific antibodies against bind to the solid phase (sample incubation). Following a washing procedure all unbound and non-specific components are washed away. During the second incubation step, the conjugate reaction, a peroxidase-conjugated anti-human IgG-antibody (anti-human-IgG-HRP) labels the previously specifically bound IgG. In a second washing procedure unbound conjugate is removed. In a third incubation step the substrate reaction takes place. The peroxidase part of the bound conjugate oxidizes tetramethylbenzidine (TMB) to a blue substance. This reaction is stopped by adding sulfuric acid and the colour changes to yellow.
The colour intensity is directly proportional upon the concentration of the PRP-specific antibodies. The absorbance is measured with an ELISA reader at 450 nm.
上海玉博生物技術有限公司在為生命科學領域提供豐富的產品與信息資源方面處于****地位，公司提供的產品涵蓋了二十多個國家近五十萬種產品，而且產品的數量與信息在不斷的增長和更新，公司提供的產品能夠使生命科學工作者加快對生物化學，分子生物學，細胞生物學以及蛋白質組學研究的認知，以及分子診斷和臨床醫學領域的應用。

產品留言

標題

聯系人

聯系電話

內容

驗證碼

點擊換一張

注：1.可以使用快捷鍵Alt+S或Ctrl+Enter發送信息!
2.如有必要,請您留下您的詳細聯系方式!